Chinese start-up breaks US monopoly in 3D imaging of biomolecules, aims for IPO in 2027
Shuimu BioSciences, a Chinese start-up specialising in advanced imaging devices for viruses and smaller biomolecules, is aiming for an initial public offering in 2027 after selling its first self-developed product this year, according to CEO Allen Guo Chunlong. The company focuses on cryo-electron microscopy (Cryo-EM), a technique that involves firing beams of electrons at flash-frozen…
